Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — November 2025

Genmab — November 2025

Planlagt Fastgjort Låst Flyttet Genmab
176 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • J Offline
    J Offline
    JKY_VH
    wrote on sidst redigeret af
    #111

    Genmab/Kepler: Dækning genoptages med neutral anbefaling og kursmål på 2100 kr.

    1 Reply Last reply
    0
    • B Offline
      B Offline
      bibob
      wrote on sidst redigeret af
      #112

      Tak @jky. Så er der plads til mere og en købsanbefaling. D 😄

      1 Reply Last reply
      0
      • J Offline
        J Offline
        JKY_VH
        wrote on sidst redigeret af
        #113

        Lige præcis bibob 🙂

        1 Reply Last reply
        0
        • E Offline
          E Offline
          E_L
          wrote on sidst redigeret af
          #114

          Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab https://www.prnewswire.com/news-releases/merus-and-halozyme-enter-global-collaboration-and-license-agreement-to-develop-subcutaneous-formulation-of-petosemtamab-302616859.html

          1 Reply Last reply
          0
          • S Offline
            S Offline
            Sukkeralf
            wrote on sidst redigeret af
            #115

            Nice - and this time no JNJ to steal all the money 🙂

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #116

              😉 Tahi Ahmadi spoke about life cycle management on the Q3 call when asked about SC for Peto, so I sort of thought they would wait a bit with it... But speeding things up makes sense with strong competition

              1 Reply Last reply
              0
              • S Offline
                S Offline
                Sukkeralf
                wrote on sidst redigeret af
                #117

                Just a moment...

                favicon

                (www.fiercebiotech.com)

                1 Reply Last reply
                0
                • L Offline
                  L Offline
                  LP90
                  wrote on sidst redigeret af
                  #118

                  Godmorgen 🙂

                  1 Reply Last reply
                  0
                  • Helge_LarsenPI-redaktørH Offline
                    Helge_LarsenPI-redaktørH Offline
                    Helge_LarsenPI-redaktør
                    wrote on sidst redigeret af
                    #119

                    Godmorgen 🙂

                    1 Reply Last reply
                    0
                    • B Offline
                      B Offline
                      bibob
                      wrote on sidst redigeret af
                      #120

                      God morgen. 🙂

                      1 Reply Last reply
                      0
                      • J Offline
                        J Offline
                        JKY_VH
                        wrote on sidst redigeret af
                        #121

                        Nogen har set lyset "Genmab/Rothschild: Hæver kursmålet til 3060 kr. fra 2860 kr.
                        Genmab har fået hævet sit kursmål til 3060 kr. fra 2860 kr. af finanshuset Rothschild & Co. Redburn.

                        Den positive anbefaling "køb" bliver i samme ombæring gentaget, viser data fra Bloomberg News.

                        Genmab-aktien lukkede fredag med et fald på 0,6 pct. i 1953,50 kr., hvilket giver et potentiale på 56,7 pct. i forhold til Rothschild & Co. Redburns nye kursmål.

                        .\˙ MarketWire"

                        1 Reply Last reply
                        0
                        • B Offline
                          B Offline
                          bibob
                          wrote on sidst redigeret af
                          #122

                          @JKY. Ja det må være julelyset der er blevet tændt. Og stjernen på toppen. 😉

                          1 Reply Last reply
                          0
                          • J Offline
                            J Offline
                            JKY_VH
                            wrote on sidst redigeret af
                            #123

                            synes nok at lyset blev slukket lidt for hurtigt:-)

                            1 Reply Last reply
                            0
                            • B Offline
                              B Offline
                              bibob
                              wrote on sidst redigeret af
                              #124

                              Følger bare markedet. 😉

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #125

                                TALVEY®▼ (talquetamab) receives positive NICE recommendation in Final Draft Guidance for treating relapsed and refractory multiple myeloma after three or more lines of treatment https://www.jnj.com/innovativemedicine/uk/media-center/press-releases/talvey-talquetamab-receives-positive-nice-recommendation-in-final-draft-guidance-for-treating-relapsed-and-refractory-multiple-myeloma

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #126

                                  Funded by Pfizer and Genmab, this project addresses the urgent barriers faced by patients and clinicians navigating recurrent or metastatic cervical cancer. https://kcmsociety.org/

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #127

                                    Next-gen treatment keeps myeloma at bay for a year / talquetamab UK https://www.myeloma.org.uk/news/next-gen-treatment-keeps-myeloma-at-bay-for-a-year/

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #128

                                      The Sub-Q Therapy That Cut Hours Off Treatment Time https://www.curetoday.com/view/the-sub-q-therapy-that-cut-hours-off-treatment-time

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #129

                                        also in reference to yesterdays announcement on Subcutaneous Formulation of Petosemtamab, even ethically you would have to wonder if you could delay SC for life cycle management...

                                        1 Reply Last reply
                                        0
                                        • Helge_LarsenPI-redaktørH Offline
                                          Helge_LarsenPI-redaktørH Offline
                                          Helge_LarsenPI-redaktør
                                          wrote on sidst redigeret af
                                          #130

                                          Servicemeddelelse: Proinvestor.com er desværre periodevis ramt af de verdensomspændende tekniske problemer der er hos Cloudflare for øjeblikket. https://www.dr.dk/nyheder

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper